Brandon S. Willis

651 total citations
13 papers, 396 citations indexed

About

Brandon S. Willis is a scholar working on Molecular Biology, Surgery and Genetics. According to data from OpenAlex, Brandon S. Willis has authored 13 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Surgery and 4 papers in Genetics. Recurrent topics in Brandon S. Willis's work include Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Brandon S. Willis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Brandon S. Willis collaborates with scholars based in United States, United Kingdom and Germany. Brandon S. Willis's co-authors include G. Stanley McKnight, Ilene L. Bernstein, Todd E. Thiele, Colleen M. Niswender, Thomas Su, Paul S. Amieux, Corinne Reimer, Austin Dulak, Jingwen Zhang and Maureen M. Hattersley and has published in prestigious journals such as Journal of Neuroscience, Blood and PLoS ONE.

In The Last Decade

Brandon S. Willis

12 papers receiving 391 citations

Peers

Brandon S. Willis
Brandon S. Willis
Citations per year, relative to Brandon S. Willis Brandon S. Willis (= 1×) peers Shanping Shi

Countries citing papers authored by Brandon S. Willis

Since Specialization
Citations

This map shows the geographic impact of Brandon S. Willis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon S. Willis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon S. Willis more than expected).

Fields of papers citing papers by Brandon S. Willis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon S. Willis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon S. Willis. The network helps show where Brandon S. Willis may publish in the future.

Co-authorship network of co-authors of Brandon S. Willis

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon S. Willis. A scholar is included among the top collaborators of Brandon S. Willis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon S. Willis. Brandon S. Willis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Wigmore, Eleanor M., Stuart C. Williamson, Amanda L. Christie, et al.. (2025). The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer. npj Breast Cancer. 11(1). 36–36.
2.
Willis, Brandon S., Hannah Dry, Wendan Xu, et al.. (2024). Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. 38(12). 2663–2674. 2 indexed citations
3.
Eberlein, Cath, Stuart C. Williamson, Susana R�os, et al.. (2024). Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British Journal of Cancer. 130(8). 1377–1387. 11 indexed citations
4.
Xu, Wendan, Philipp Berning, Tabea Erdmann, et al.. (2022). mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 37(1). 178–189. 18 indexed citations
5.
Willis, Brandon S., Hannah Dry, Wendan Xu, et al.. (2021). Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 1870–1870. 1 indexed citations
6.
Zhang, Jingwen, Austin Dulak, Maureen M. Hattersley, et al.. (2018). BRD4 facilitates replication stress-induced DNA damage response. Oncogene. 37(28). 3763–3777. 67 indexed citations
7.
Young, Lucy A., Oona Delpuech, Brandon S. Willis, et al.. (2018). Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models. Cancer Research. 78(13_Supplement). LB–263. 3 indexed citations
8.
Wenglowsky, Steve, Li Ren, Jonas Grina, et al.. (2014). Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase. Bioorganic & Medicinal Chemistry Letters. 24(8). 1923–1927. 16 indexed citations
9.
Willis, Brandon S., Colleen M. Niswender, Thomas Su, Paul S. Amieux, & G. Stanley McKnight. (2011). Cell-Type Specific Expression of a Dominant Negative PKA Mutation in Mice. PLoS ONE. 6(4). e18772–e18772. 33 indexed citations
10.
Abdel-Majid, Raja M., Mark Barnett, Brandon S. Willis, et al.. (2006). Involvement of Protein Kinase A in Patterning of the Mouse Somatosensory Cortex. Journal of Neuroscience. 26(20). 5393–5401. 32 indexed citations
11.
Niswender, Colleen M., Brandon S. Willis, Ian R. Sweet, et al.. (2005). Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A. genesis. 43(3). 109–119. 35 indexed citations
12.
Howe, Douglas G., Christine M. Clarke, Brandon S. Willis, et al.. (2005). Inhibition of protein kinase A in murine enteric neurons causes lethal intestinal pseudo-obstruction. Journal of Neurobiology. 66(3). 256–272. 26 indexed citations
13.
Thiele, Todd E., et al.. (2000). High Ethanol Consumption and Low Sensitivity to Ethanol-Induced Sedation in Protein Kinase A-Mutant Mice. Journal of Neuroscience. 20(10). RC75–RC75. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026